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Prognosis of idiopathic membranous nephropathy: A methodologic
meta-analysis. Results in studies on prognosis and treatment of membra-
nous nephropathy are conflicting. The aim of this investigation was to
analyze the methodology of the existing research and to identify sources of
these conflicting results. Studies published on prognosis of membranous
nephropathy from 1970 to 1995 were identified using a Medline database
literature search. The criteria for inclusion in the methodologic analysis
were: (1) original article; (2) cohort study or clinical trial with  50 adults;
(3) zero time near the diagnostic renal biopsy; and (4) follow-up  six
months. Ten well-accepted methodologic standards for prognostic re-
search were applied to each study and the compliance was evaluated.
Among the 26 studies that met the inclusion criteria, the median number
of standards fulfilled was 4 and the highest was 7. The proportion of
studies adhering to the individual standards was: (1) adequate diagnostic
criteria, 35%; (2) definite end point, 46%; (3) adequate analysis of a
surrogate end point, 52%; (4) analysis of baseline severity, 0%; (5)
indication of baseline frequency for candidate predictors, 35%; (6)
reproducible classification of predictors, 85%; (7) multivariable analysis,
50%; (8) identification of the variables' importance in multivariable
analysis, 38%; (9) evaluation of the effect of treatment on predictors, 19%;
and (10) adequate analysis of censored patients, 58%. We conclude that
basic methodologic principles have frequently been disregarded. The
consideration of these standards in future research can improve the
interpretability and applicability of results and help reconcile conflict
when results are compared among different studies.
Membranous nephropathy is the most common cause of the
nephrotic syndrome in adults [1, 2]. About 25% of the patients
will enter into spontaneous remission, whereas about one third to
one half will develop end-stage renal failure or die from compli-
cations of the nephrotic syndrome. Although many studies have
been done on prognosis of the disease and on the effect of
different therapies, they give conflicting results (Table 1). Because
of the inability to demarcate the different prognostic groups for
risk stratification in trials and to predict outcome accurately for
individual patients, it has been concluded that further studies on
prognosis of membranous ncphropathy are needed [3, 4]. This
conclusion is supported by the hazards related to therapy with
immunosuppressive drugs. Reliable predictors are needed for a
targeted application of these therapies to patients with poor
prognosis, for whom the expected benefit might outweigh the risk,
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and to avoid treating patients with a good chance for spontaneous
remission.
A small sample size, inadequate duration of follow-up and
variable study quality have been related to the hitherto inconclu-
sive results [5]. However, the methodologic quality of the existing
research as an important source for conflicting results has not
been analyzed systematically. The aim of this investigation was
therefore methodologic: to identify sources for distortion or bias
that can create problems in reproducibility and applicability of the
predictors and, thus, lead to inconsistent results. Such problems
might arise from the choice of diagnostic criteria, the selection
and appraisal of outcome events, the quantitative scope of the
spectrum of disease, the choice and classification of candidate
predictor variables, the choice of the methods used for prognostic
analysis, the impact of treatment, and the effect of censoring on
the prognostic results. We therefore applied a set of methodologic
standards addressing these problems [6—9], and determined each
study's compliance with the individual standards. We wanted to
offer strategies that will help improve the clinical applicability, the
accuracy and interpretability of the identified predictors, and to
reveal underinvestigated topics for future research. In addition,
these standards might be helpful for investigators trying to
evaluate the quality of studies before pooling their results in
quantitative meta-analyses [10—12].
Methods
Selection of studies
The studies on prognosis of idiopathic membranous nephrop-
athy were identified with a Medline database literature search and
a check of the cited references. A broad search using the terms
"membranous nephropathy" or "membranous glomerulonephri-
tis" yielded 1715 articles, The inclusion criteria were: (1) original
article published between January 1970 and December 1995; (2)
cohort study or randomized trial including 50 adults; (3)
inception cohort with zero time near the date of the diagnostic
renal biopsy or corresponding to the date of randomization in a
clinical trial; (4) follow-up  six months. Investigations that
included patients with secondary forms of menibranous nephrop-
athy were eligible, if separate prognostic results were reported for
the subgroup with an idiopathic form. These inclusion criteria
were met by 26 reports [13—38]: five cohort studies with untreated
patients; five randomized controlled trials, from which six reports
were included (2 reports from 1 trial [18, 28] with different
analyses after different lengths of follow-up); and 15 observational
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Serum creatinine [17, 23, 29, 33, 38] [19, 27, 28, 31, 37]
Protcinuria [23, 331 [19, 27, 28, 36, 37]
Nephrotic syndrome [17, 31] [29, 36, 38]
Serum albumin [19] [27, 29, 33, 37]
Glomerular stage — [19, 28, 291
Tubulointerstitial lesions [28, 29, 38] —
Vascular lesions [38] [28]
Hypertension — [19, 23, 28, 29, 31, 33, 36,
37, 38]
Hypercholesterolemia [38] [23, 36]
Age [17, 361 [19, 23, 27, 28, 29, 31, 33,
37, 38]
Sex [17, 19,31, 36]
Numbers indicate reference citations for
[23, 27, 28,29, 33, 37, 38]
the studies in which the
variable was reported.
studies of patients receiving uncontrolled treatment for membra-
nous nephropathy.
Methodologic standards, rationale and rating criteria
From well-accepted methodologic standards for prognostic
research [6—9], we selected 10 principles which address major
problems that might become sources of conflicting results because
of bias, distortion, or lack of reproducibility. Each eligible study
was then evaluated on its compliance with the individual stan-
dards.
Standard 1: Adequate diagnostic criteria. The purpose of this
standard is to ensure that patients with the same disease are
included. Besides this issue of reproducibility, the results will only
be applicable if distortion of the study group due to heterogeneity
is prevented, which can occur if patients with a secondary form of
membranous nephropathy are admixed to patients with an idio-
pathic form, because each has a different prognosis.
The diagnostic criteria were adequate if the criteria for the
histologic diagnosis of membranous nephropathy were described
[13, 39, 40] and if the diagnosis was confirmed with immunohis-
tochemistry or electron microscopy. In addition, the reader had to
be reassured that equal diagnostic testing was done for each
patient to exclude secondary forms of membranous nephropathy.
Standard 2: Choice of a definite endpoint. The end point chosen
should be unambiguous, clinically relevant and definitive. The end
point "end-stage renal failure requiring renal replacement ther-
apy" should always be analyzed because: (1) it is the only
unambiguous end point, reflecting the irretrievable loss of renal
function; and (2) the principal goal of prognostication in mem-
branous nephropathy is to demarcate the group at highest risk
from the group at lowest risk for end-stage renal failure.
Another acceptable end point preferred by some investigators
is "complete remission of proteinuria," which has been found to
he associated with a favorable prognosis [41—441. However,
because remissions are often non-sustained and relapses can
occur, followed in rare occasions by deterioration of renal func-
tion [2, 14, 21, 22, 36, 44—461, the choice of the outcome end-stage
renal failure is preferable.
The total number of deaths should be indicated because death
due to complications related to renal disease or due to other
causes may remove patients who might otherwise have been at
risk for developing the end point. Unless total deaths are re-
ported, a treatment that reduces renal deaths while increasing
total deaths (for example, due to an increase in cancer deaths) will
be improperly evaluated.
The standard was fulfilled if a definite end point was used and
if the total number of deaths was reported.
Standard 3: Adequate analysis of a surrogate end point. If a
surrogate end point is chosen for analysis, it must be specified
appropriately. An appropriate specification should include: (1)
the definition of the end point; and (2) a description of all the
possible events contained in the failure category of a binary
outcome event, together with the frequency of these events.
The purpose of the standard is to prevent results from being
non-reproducible and non-interpretable because different surro-
gate end points are used differently by different investigators. The
variability in the choice of surrogate end points and their defini-
tions is demonstrated in Table 2. In addition, the surrogate end
points used can range from a mild degree of proteinuria to severe
deterioration of renal function (Fig. 1). Thus, the content and the
importance of the events may be highly variable and depend on
the severity of functional impairment reflected by the surrogate
end point. To prevent misleading interpretation of prognostic
results, the frequencies for all possible outcome categories need
to be reported.
Standard 4: Adequate analysis of baseline severity. The scientific
quality of the identified predictors depends on the inclusion of
cogent variables in the analysis. The omission of an important
variable is often responsible for predictors that do not perform
consistently, or that give misleading results in later application.
The standard therefore required analytic consideration of all the
important aspects of illness severity at baseline that might affect a
patient's long-term prognosis. Criteria for the evaluation of
severity of renal disease have been proposed by the Council on the
Kidney in Cardiovascular Disease of the American Heart Asso-
ciation [47]. They include severity of signs and symptoms, severity
of renal functional impairment, and level of performance of
physical activity. However, the severity of co-morbidity, which is
an essential component of baseline severity, has been entirely
omitted.
Because no classification system has yet been developed that
combines all these relevant aspects, the standard required that at
least the following six different baseline characteristics be used for
analysis of baseline severity: (1) severity of renal functional
impairment; (2) severity of histologic lesion according to estab-
lished staging systems of membranous nephropathy [13, 39, 40];
(3) hypertension; (4) severity of co-morbidity classified, for exam-
ple, according to the classification systems by Kaplan [48] or
Charlson [491; and the demographic features (5) age and (6) sex.
To be evaluated appropriately, these six characteristics had to he
represented by at least one variable for each characteristic in the
prognostic analysis, or by an unambiguous statement that one or
more characteristics had been used as an exclusion criterion.
Standard 5: Indication of baseline frequency fbr cnicial variables
not identified as predictors. This standard is closely related to the
preceding standard and has two purposes: (1) The indication of
the quantitative spectrum of illness severity is needed for and
adequate interpretation of the identified predictors. The predic-
tors identified from cohort A with 80% severely ill and 20% mildly
ill patients will differ from the predictors identified in cohort B
Table 1. Results for variables evaluated in multivariable analyses as
predictors for end-stage renal failure or renal insufficiency in idiopathic
membranous nephropathy
Variables Predictive Not predictive
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Table 2. Surrogate end points chosen in studies on prognosis of
idiopathic membranous nephropathy
Surrogate end point Definition
Reduction of proteinuria to 0.2 1—2.0 g/day
with normal serum creatinine [18, 23, 34]
Proteinuria 0.2—2.0 g/day, serum albumin
 2.5 g/dl [36]
Proteinuria 0.1—3.0 g/day, serum protein
 60 g/liter, serum albumin 30 g/liter
[311
Reduction of protein excretion of > 50%
from baseline values, and protein
excretion  3.0 g/day [271
Persistent fall of proteinuria to < 3.0 g/day
[24]
Mild proteinuria < 1.0 g/day or moderate
proteinuria 1.0—3.5 g/day [221
Substantial diminution of proteinuria with
increase of serum albumin, with
diminution of serum creatinine if
previously elevated, with rise in
creatinine clearance or maintenance of
normal serum creatinine or creatinine
clearance [16]
Disappearance of nephrotic syndrome,
persistence of mild proteinuria with
normal renal function [15]
Proteinuria > 2.0 g/day [231
Proteinuria > 2.0 g/day and serum
creatinine stable or increase of <50%
over baseline levels [181
No definition [261
Continuance of nephrotic syndrome with
or without decreased renal function [161
Creatinine clearance < 70 ml/min/1.73 m2
or serum creatinine > 1.5 mg/100 ml
[20]
25% decrement in the initial creatinine
clearance [27]
Serum creatinine increase of  50% over
baseline levels [18, 28, 34]
Serum creatinine doubling or reaching
 400 mol/litcr [171
No definition [21, 24]
No definition [35]
No definition [20]
Creatinine clearance <60 ml/min/1.73 m2
persisting  12 months [331
Persistent rise of serum creatinine to
> 125 j.rmol/liter and/or decrease of
creatininc clearance to <65 ml/min/1.73
m2 [37]
Serum creatinine > 400 rmol/liter [30]
Serum creatinine > 450 jzmol/liter [23]
Numbers in brackets indicate the reference citations for the studies in
which the surrogate end point was used.
with 20% severely ill and 80% mildly ill patients. (2) Although all
crucial variables may have been included in the prognostic
analysis, they can only be designated "significant" if present in a
sufficiently large number of patients. If all the crucial variables are
identified as predictors, the indication of their frequency is not
necessary. If, however, a variable has not been identified as a
predictor, its baseline distribution must be reported to distinguish
if the variable has been entirely omitted from the analysis, or if it
could not achieve statistical significance because of a too low
frequency.
For dimensional variables, such as age, baseline frequency must
be indicated for at least two categories, such as age < 65 years
and > 65 years, because the arithmetical mean can be greatly
influenced by outlier values.
Standard 6: Reproducible classification of candidate predictor
variables. Different demarcations and combinations of variables or
categories may lead to entirely different entities. This method-
ologic standard is intended to let the reader know what is meant
by such terms as "deteriorated renal function," "hypertension," or
"higher age." The requirement was that suitable specification be
given to the values used for demarcation.
Standard 7: Use of multivariable analysis for identification of
predictors. Multivariable analysis should be performed to evaluate
the candidate predictor variables, and to examine if a predictor
remains predictive when tested in the presence of other prognos-
tically important variables. An analysis was considered multivari-
able if it examined the simultaneous effect of two or more
independent variables on a specific outcome.
In our evaluation, a multivariable analysis could be a complex
mathematical model such as multiple linear or logistic regression
analysis, discriminant function analysis, the Cox model, or it could
be a more simple analysis, such as a stratified analysis, or a point
score or composite index.
Standard 8: Identification of the variables' importance in multi-
variable analysis. The purpose of this standard is (a) to reveal
differences in the probabilistic boundaries used for decisions
about "statistical significance," and (b) to identify a variables'
quantitative importance.
Different predictors may emerge if different probabilistic
boundaries are used for "statistical significance." Because the
indexes of statistical significance are highly dependent from
sample size, even a relatively unimportant variable may become a
predictor if the study is large enough, because the variable has
achieved a P value of < 0.05. Only an index of the variables'
quantitative importance, such as the odds ratio or the relative risk,
which does not depend on sample size, will allow comparison and
interpretation of results across studies [6, 50].
The probabilistic boundaries used could be a P value, confi-
dence interval, or demarcation such as a value of "F to enter." The
quantitative importance could be indicated in algebraic multiva-
riable models with indexes such as a preferably standardized
beta-coefficient, the relative risk or odds ratio. If the results were
reported with ranks and strata, the magnitude of the gradients
between the scores and the strata would indicate their quantitative
importance.
The standard was fulfilled, if the probabilistic boundaries and
an index of quantitative importance were reported.
Standard 9: Evaluation of the effect of treatment on predictor
variables. During the last few years, various therapies have been
used to influence the course of membranous nephropathy. The
favorable results reported for some patients in controlled trials
and uncontrolled observational studies could, however, not he
confirmed by others.
If effective new treatments have deferred or prevented the
outcome event, a previously identified predictor variable might
lose its impact. Conversely, a new variable may seem predictive if
Partial remission
Partial remission
Partial remission
Partial response
Partial remission for
nephrotic patients
Incomplete
remission
Improved
Clinical
improvement
Persistent
proteinuria
Unchanged
Stable renal function
Not improved or
worse
Impaired renal
function
Decline in renal
function
Worsening
Deterioration
Deterioration of
renal function
Renal dysfunction
Renal insufficiency
Chronic renal
insufficiency
Chronic renal
insufficiency
Renal failure
End-stage renal
failure
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it reflects a harmful therapeutic effect. Consequently, the predic-
tors identified from one cohort may differ from the predictors
identified in the other cohort, if different treatments were used.
For an appropriate interpretation, the standard requires that
the effect of treatment is considered in the prognostic analysis.
This can be done in two steps: (1) The candidate predictors can be
analyzed for the total group of patients, irrespective of treatment;
and (2) the multivariable analysis can be repeated and checked to
see if the predictors change when treatment is added as an
additional variable.
We considered the standard fulfilled if the investigators had
analyzed for the impact of treatment on the predictors, or if the
report contained a statement that a specific treatment was either
used for each patient of the cohort or not used at all during the
study period.
Standard 10: Adequate reporting and analysis for censored pa-
tients. The standard required that the number of patients censored
together with the reason for censoring should be reported, and
that the censored patients be adequately considered in the
analysis.
When each member of the cohort is followed from a uniform
zero time over an identical observation period, the incidence rate
of the end point will be a good measure of the overall risk. A
problem occurs if not all members of the cohort are followed for
equal lengths of time. When patients are lost from the study, they
are called censored. The main sources for censoring are: patients
are lost from follow-up, removed from the cohort by a competing
event, such as an unrelated death, or have an insufficient duration
of follow-up to develop the end point. Losses to follow-up may
become a source for biased results, because patients lost to
follow-up have often a worse prognosis with a high incidence of
end points [51—531. The lower the risk of a prognostic end point,
the greater will be the potential effect of patients lost to follow-up.
To make use of the partial follow-up data until censoring occurs,
the method of life-table analysis can be used, which indicates how
risk can change over time [54]. Because life-table analysis cannot
correct for the bias arising from censoring, the number of patients
censored and reason for censoring should be reported.
Results
Compliance with the individual standards
The overall compliance of the 26 studies with the 10 method-
ologic standards is summarized in Table 3.
Standard 1: Adequate diagnostic criteria. Twenty-one studies
adequately specified the criteria used for histologic diagnosis. In
20 studies the diagnosis was confirmed with immunohistochemis-
Fig. 1. Range of possible outcome categories in
membranous nephropathy. The two definite end
points are located at both ends of the outcome
scale. "Complete remission" reflects patients
with the best prognosis and "end-stage renal
failure" or "death" reflects those patients with
the worst prognosis. The surrogate end points
chosen between the definite end points are
functional end points from which changes can
occur towards improvement or deterioration.
Because different surrogate end points reflect
different degrees of functional impairment,
different predictors may result.
Table 3. Compliance with 10 methodologic standards in 26 studies [13—
38] on prognosis of membranous nephropathy
Studies
10 Methodologic standards
(in %)
complying
with the
standard References
1. Adequate diagnostic criteria 35% [14, 18, 20, 23, 25, 27,
34, 35, 371
2. Choice of a definite end point 46% [13, 15, 16, 19, 20, 22, 24,
26, 29, 31, 36, 381
3. Adequate analysis of a surrogate 52%" [13—15, 18, 23, 27,28,
end point 32—34, 36]
4. Adequate analysis of baseline 0% —
severity
5. Indication of baseline frequency 35% [19, 23, 24, 27, 29,32,
for crucial variables not identified 34—36]
as predictors
6. Reproducible classification of 85% [13—16, 19—27, 29—37]
candidate predictor variables
7. Use of multivariable analysis for 50% [13, 17, 19, 23, 27, 28,29,
identification of predictors 31, 33, 34, 36—38]
8. Identification of the variables' 38%t [19, 28, 31, 33,341
importance in multivariable
analysis
9. Evaluation of the effect of 19% [15—17, 31,361
treatment on predictor variables
10. Adequate reporting and analysis 58% [13, 14, 17, 19, 22—24,
of censored patients 27—29, 31, 33, 34,
36,37]
* Twenty-one studies did an analysis for a surrogate end point.
t Predictors were identified with a multivariable analysis in thirteen
studies.
See text for a detailed description of the standards.
try or electron microscopy. The excluded secondary forms of
membranous nephropathy were specified in 14 reports that also
contained a statement that reassured equal diagnostic testing for
each patient. Overall, nine studies (35%) fulfilled all the require-
ments.
Standard 2: Choice of a definite end point. Ten studies chose the
outcome "end-stage renal failure" [15, 16, 19, 22, 24, 26, 29, 31, 36,
38] and three studies chose the outcome "complete remission"
[13, 15, 20]. One report contained separate analyses for both,
complete remission and end-stage renal failure [15]. The total
number of deaths was reported in 21 studies. The standard was
fulfilled by 12 studies (46%), which used a definite end point and
reported the total number of deaths.
Low risk
A
High risk
Complete remission Definite end point
Partial remission
Surrogate end points
Deterioration of renal function
1
End stage renal failure (ESRF) Definite end point
Death (with or without preceding ESRF)
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Standard 3: Adequate analysis of a surrogate end point. A
surrogate end point was chosen in 21 studies for prognostication
(81%). However, only 11 of the 21 reports (52%)specified the end
point reproducibly and indicated the frequencies for the possible
discrete outcome categories.
Standard 4: Adequate analysis of baseline severity. None of the
studies did an appropriate analysis for co-morbidity. Even when
the standard was made more lenient and restricted to the five
remaining conditions for describing baseline severity (severity of
renal functional impairment, severity of histologic lesion, hyper-
tension, age, and sex), it was fulfilled by only seven studies (27%)
[14, 19, 24, 28, 29, 32, 381.
Standard 5: Indication of baseline frequency for crucial variables
not identified as predictors. Only nine reports (35%) indicated the
baseline frequency for the crucial variables that had not emerged
predictive from the prognostic analyses.
Standard 6: Reproducible classification of candidate predictor
variables. Twenty-two studies (85%) fulfilled this standard. The
high compliance was achieved because most often the candidate
predictors were laboratory parameters, whereas clinical symptoms
and findings, which present a greater challenge for appropriate
specification, were omitted from the prognostic analyses.
Standard 7: Use of multivariable analysis for identification of
predictors. Multivariable analysis was used in 13 studies (50%) for
prognostication. A predictive score based on the multivariable
results was developed in only one study [33]. None of the 26
studies attempted to validate the results.
Standard 8: Identification of the variables' importance in multi-
variable analysis. The stochastic and the quantitative significance
of the predictor variables was identified in only four of the 13
studies (31%) that used multivariable analysis [19, 28, 31, 34].
Four other studies indicated the stochastic significance using P
values but did not report the quantitative importance of the
predictors [23, 29, 37, 38], whereas one other study indicated the
predictors' quantitative importance using beta-coefficients with-
out reporting the threshold used for statistical significance [33]. If
the latter report is accredited for indicating at least the clinically
relevant quantitative importance, the standard was fulfilled by five
studies (38%).
Standard 9: Evaluation of the effect of treatment on predictor
variables. Full compliance was present in only five reports (19%)
[15—17, 31, 36]: four studies prevented the problem by investigat-
ing an untreated cohort, and one study did a stratified analysis to
evaluate the impact of treatment on the predictors. Most studies
(81%) showed no awareness of the problem.
Standard 10: Adequate reporting and analysis of censored patients.
Thirteen studies (50%) reported the number and reasons for
censoring and performed an adequate analysis of the censored
patients [14, 19, 22—24, 27—29, 31, 33, 34, 36, 37]. Seven studies
reported only the number of censored patients and the reason for
censoring [13, 15, 17, 18, 30, 35, 38], and three studies did a
life-table analysis without indicating number and reason for
censoring [15, 21, 37]. Because only a few patients were censored
in two reports [13, 17], it seemed that they should be exempted
from the request for life-table analysis. With these two studies
added, the standard was fulfilled by 15 studies (58%).
Discussion
Conflicting and uncertain results regarding prognosis and treat-
ment of membranous nephropathy prevent a reliable demarcation
of the different risk strata and the identification of an effective
therapy. It is generally recognized that further and improved
studies are needed [3, 4]. This investigation was done to evaluate
the adherence with methodologic principles for prognostic re-
search in the published reports. We wanted to illuminate the
problems and offer strategies to prevent them, so that the quality
and applicability of prognostic results could be improved in future
studies.
The results show that basic methodologic principles have
frequently been disregarded in the published studies. The maxi-
mum number of standards fulfilled could be 10. However, none of
the studies fulfilled 10, 9 or 8 standards. Only three reports met
seven standards [19, 34, 36]. The minimum number of standards
fulfilled was one and the median was four.
The diversity of the three studies that adhered to 7 standards
[19, 34, 36], which was the highest compliance achieved, makes the
findings difficult to compare and to reconcile. The end point was
"end-stage renal failure" in two studies [19, 36], determined in
one study after a median follow-up of 39 months [36], whereas the
median follow-up was 76 months in the other [191. The end point
of the third study was "complete or partial remission" [34].
Therefore, the predictors identified in this latter study cannot
directly be compared with the results from the earlier mentioned
investigations.
Based on our observations the methodologic standards should
be considered as guides, not as grades. A study that gets 9 of 10
points may receive a high total score, but may nevertheless be
irretrievably flawed by the defects in the missing feature. Con-
versely, a study that gets only 6 of 10 points may be quite good
despite minor violations that produce a loss of four points. In
addition, the predictors identified in a randomized controlled
trial—the methodologic paragon for assessing evidence—may be
better despite some flaws in reporting than the prognostic results
obtained in a cohort study. We are aware that in some studies the
investigators may actually have had the data required by the
standards, for example on censored patients, but did not report it
in their paper, either because they are driven to brevity by
editorial policy, or because the investigators did not realize the
importance of reporting these data. The need for further improve-
ments in reporting and design of randomized controlled trials to
accurately assess the scientific merit of their results has recently
been recognized, and corresponding guidelines have been pro-
posed [55, 56]. For our evaluation of prognostic research, rather
than create a rigid scoring system for quality, our aim was to
describe general methodologic problems that investigators could
note and try to avoid in future research.
We would particularly emphasize five methodologic standards,
because these standards have often been violated and because we
believe that they are essential for improving quality in future
research.
(1.) Definite end point. A definite outcome event for prognos-
tication was analyzed in only 12 studies. The relatively short
follow-up in many of the published studies may have been one
reason for choosing a surrogate end point instead of a definite
outcome. A comparison of the length of follow-up showed that
the average observation period was shorter in the 15 studies that
analyzed for a surrogate end point and also reported the duration
of follow-up, compared to the 12 studies that analyzed for a
definite end point (56.9 months versus 78.2 months, respectively).
Because the data on long-term development of renal function
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are often missing in the published studies, the important question
of whether cytotoxic treatment prevents renal failure in membra-
nous nephropathy could not be answered in a recent meta-analysis
by Imperiale, Goldfarb and Berns [57]. When the authors com-
bined the data from five therapeutic trials containing analyses for
the end point "complete or partial remission of proteinuria," they
could show a beneficial effect of cytotoxic agents for resolving
nephrotic-range proteinuria. However, as the authors stated
themselves, whether treatment-related remissions of proteinuria
will be predictive of the long-term preservation of renal function
remains conjectural [571.
Thus, although preliminary analyses for a surrogate end point
are acceptable for exploratory analyses, only future studies with
appropriate analyses for the definite end point end-stage renal
failure will be able to verify prognostic results and provide the
necessary data for a definite answer regarding long-term efficacy
of treatment within distinct prognostic groups in a randomized
controlled trial.
(2.) Baseline severity. The analysis of baseline severity consists of
the severity of renal disease and co-morbidity. This analysis is tied
to standard #3 (below) in importance.
(3.) Quantification of the spectrum of illness severity. The analysis
of the baseline severity plus the quantification of the spectrum of
illness severity included in the study are crucial for correct
interpretation and for the subsequent applicability of predictors,
because the spectrum of disease from which the predictors are
derived determines the spectrum of patients to which they can be
applied. In addition, the most sophisticated statistical analysis
cannot produce clinically relevant results if important informa-
tion, such as the severity of disease, has been omitted from the
analysis. None of the 26 studies evaluated had appropriately
analyzed for co-morbidity. Even the remaining characteristics
(severity of renal functional impairment, severity of histologic
lesion, hypertension, age and sex) were analyzed in only 27% of
studies.
(4.) Multivariable analysis. This was used in only 50% of the
studies. Recently, however, multivariable analyses have become
more popular. When the studies included in our evaluation are
ranked chronologically from the first to the last studies published,
the last quintile contains four of five studies (80%) performing a
multivariable analysis, which is almost twice as many compared to
the preceding 21 studies in which multivariable analysis was used
in only 9 reports (43%). Multivariable analyses should be used in
all future investigations because they permit the determination of
the predictive impact of each variable when all the candidate
predictors are examined in relation to each other.
(5.) Treatment impact More investigations are needed on the
impact of treatment on predictor variables. Whenever a specific
treatment is used for membranous nephropathy, its effect should
be evaluated by performing the prognostic analysis with and
without the treatment variahle included to check if the identified
predictors change. The disappearance of a previously predictive
variable can either mean that the treatment was so effective as to
defer or prevent the unfavorable outcome, or, the identification of
a new variable might be a marker of a undesired side effect of
treatment.
In summary, the goal of this investigation was to identify
methodologic problems in studies on membranous nephropathy,
which can be avoided in future prognostic research. Because
non-adherence with the described standards can lead to bias,
distortion, ambiguity, and to problems in reproducibility and
applicability of results, consideration of these methodologic stan-
dards can improve the scientific quality and interpretability of
results in future studies on prognosis of membranous nephropa-
thy, and will help to demarcate clinically important prognostic
groups.
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